What Hemotag does

Hemotag, a registered trademark of Aventusoft, LLC, is a private medical device company headquartered in Boca Raton, Florida, that develops a non-invasive cardiac monitoring platform for heart failure management. The company's core product, the HEMOTAG Cardiopulmonary Assessment System, combines a wearable recording device with a companion mobile application (the Licensed Application) to track cardiac time intervals and cardiopulmonary parameters across multiple cardiac chambers, with the stated purpose of predicting clinical decompensation in patients with acutely decompensated heart failure. The device is FDA-cleared and is supported by six granted US patents (D972150, 8475396, 10165985, 10362997, 10531839, 11490849) plus pending applications. Hemotag has built an evidence base of 600+ enrolled patients across 8 clinical studies and 25 peer-reviewed publications in journals including the Journal of the American College of Cardiology, the Journal of Cardiac Failure, and Cardiovascular Science.

The company operates a primarily enterprise B2B/clinical-research go-to-market. Its commercial channel is the HEMOTAG Early Access Program (EAP), a structured 6-12 month engagement open to large academic medical centers and community hospitals, featuring NIH-sponsored research terms, patient reimbursement provisions, and co-authorship opportunities for participating clinicians. Pricing is quote-based with no public disclosure, and revenue is generated through hardware sales to healthcare institutions augmented by recurring engagement revenue from research collaboration and technology deployment under the EAP. Current operating geography is the United States only.

Hemotag's customer and partner base is concentrated among leading US clinical institutions, including UF Health, Memorial Healthcare System, Cleveland Clinic Florida, Baylor Scott and White Health, the University of Miami, and Mount Sinai. The company has received multi-year non-dilutive recognition and funding from federal sources, including the National Heart, Lung, and Blood Institute (NHLBI), the National Institute on Minority Health and Health Disparities (NIMHD), the National Institute of Biomedical Imaging and Bioengineering (NIBIB), the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the NSF, DARPA, and the U.S. Department of Defense, the latter via six consecutive annual awards from 2018 through 2024. Hemotag is also an ATC portfolio company, a 2025 MedTech Innovator Asia Pacific Top Innovator, and a 2020 Florida Companies to Watch honoree. No disclosed funding rounds, revenue figures, executive leadership information, or institutional equity investors appear in the available source material.

Name

Hemotag

Legal name

Aventusoft, LLC

Website

https://hemotag.com

Company type

Private

Operating status

Operating

Headcount range

11–50 employees

Short description

Hemotag (a trademark of Aventusoft, LLC) develops a non-invasive, FDA-cleared cardiac monitoring device and companion mobile app for heart failure management, serving US hospitals, academic medical centers, and research institutions through clinical partnerships and an Early Access Program.

Ownership category

akta.pro rank

Product category

Cardiac Monitoring Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Hemodynamic Monitoring & Cardiac Diagnostics (Cath Lab, FFR/IVUS/OCT) (HLAHAFAI)

akta.pro secondary industry

Cardiology Telemedicine Platforms (HLALAGAB)

Keywords

• Non-invasive cardiac monitoring
• Heart failure management
• Medical device manufacturing
• Cardiac time intervals
• Cardiopulmonary assessment

Headquarters

HQ city

Boca Raton

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Medical Device Sales: HEMOTAG is a medical device sold to healthcare institutions. The device is used by patients under the direction of qualified healthcare providers for cardiac monitoring.
2. Early Access Program / Technology Access: Healthcare institutions gain priority access to advanced research technology through the Early Access Program which includes NIH-sponsored research terms, reimbursement for patients, and extended trial periods. This creates recurring engagement revenue through research collaboration and technology deployment.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

HEMOTAG is a non-invasive medical device system designed specifically for heart failure monitoring that tracks performance of multiple cardiac chambers via cardiac time intervals. It pairs the HEMOTAG Recording Device with a companion mobile application (Licensed Application) to deliver continuous cardiopulmonary assessment and prediction of clinical decompensation for patients under healthcare provider direction. The offering is sold to healthcare institutions, research centers, and hospital systems through an Early Access Program.

Product overview

Hemotag (a registered trademark of Aventusoft, LLC) offers a unified medical device ecosystem centered on the HEMOTAG Cardiopulmonary Assessment System — a non-invasive cardiac monitoring platform combining hardware and mobile software. The core system comprises the HEMOTAG Recording Device (a wearable/mobile cardiac sensor) and the HEMOTAG Mobile Application (Licensed Application), which together track cardiac time intervals to predict heart failure decompensation. The Early Access Program provides institutions early access to the technology with NIH-sponsored research support. A 2026 research track branded 'Full-Spectrum Heart Failure Management' extends the platform's multi-chamber cardiac monitoring capabilities. All components are governed by a single integrated regulatory and privacy framework under Aventusoft, LLC.

Differentiator

Problem solved

Functional benefit

Products and services

• HEMOTAG Cardiopulmonary Assessment System A non-invasive medical device system for continuous cardiac monitoring and heart failure management that predicts clinical decompensation by tracking cardiac time intervals and cardiopulmonary parameters. Designed for healthcare providers treating patients with acute or chronic heart failure.
• HEMOTAG Mobile Application (Licensed Application) A companion mobile application that operates exclusively with authorized HEMOTAG devices to display cardiac monitoring data and support heart failure patient management under healthcare provider direction.
• HEMOTAG Early Access Program A program providing healthcare institutions exclusive early access to HEMOTAG technology for clinical validation, featuring NIH-sponsored research participation, dedicated support, and research collaboration opportunities including co-authoring publications. Program runs 6-12 months with implementation, training, and ongoing support.

Quantifiable outcome

• Published in Journal of the American College of Cardiology for predicting clinical decompensation in heart failure in the inpatient setting
• +2 more outcomes

Named customers6 records

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature3 records

Partnerships

Twelve partnerships are on record, tiered core, flagship and minor.

• UF HealthcoreStrategic or Co-development PartnerClinical research partner collaborating on advancing cardiac care science through validation trials and clinical studies for heart failure monitoring technology.
• Memorial Healthcare SystemcoreStrategic or Co-development PartnerClinical research partner contributing to evidence base for better heart failure care through joint studies and research initiatives.
• Cleveland Clinic FloridacoreStrategic or Co-development PartnerLeading medical institution partner advancing cardiac monitoring technology through clinical validation and research collaboration.
• Baylor Scott and White HealthcoreStrategic or Co-development PartnerMajor health system partner collaborating on research initiatives and clinical validation of cardiac monitoring technology.
• University of MiamicoreStrategic or Co-development PartnerAcademic research partner advancing the science of cardiac care through research collaboration and academic publications.
• Mount SinaicoreStrategic or Co-development PartnerAcademic medical center partner involved in clinical research for heart failure care advancement.
• MedTech Innovator Asia PacificflagshipGTM or Marketing PartnerNamed top innovator in 2025 Asia Pacific Grand Finals competition, providing significant visibility and credibility for medical technology advancement.
• BioFloridaminorGTM or Marketing PartnerFlorida bioscience industry association providing networking and recognition for biotechnology companies.
• Trade AmericasminorGTM or Marketing PartnerInternational trade organization supporting Latin America and Caribbean business development.
• HLTHcoreGTM or Marketing PartnerHealthcare innovation conference providing visibility and networking within the healthcare technology ecosystem.
• Florida Atlantic University Tech RunwaycoreGTM or Marketing PartnerUniversity accelerator program providing startup support, mentorship, and ecosystem connections in South Florida.
• GrowFLminorGTM or Marketing PartnerFlorida entrepreneurial support organization providing resources and recognition for growing companies.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• iRhythm Technologies: iRhythm's Zio long-term cardiac monitoring patch is a direct competitor in non-invasive ambulatory cardiac monitoring. Targets similar cardiology and electrophysiology customers with AI-driven arrhythmia detection from continuous ECG data.
• Abbott: Abbott's CardioMEMS HF System is a direct competitor in remote heart failure monitoring, using implantable pulmonary artery pressure sensors to predict decompensation. Most analogous commercial-stage product to HEMOTAG's heart failure monitoring value proposition.

Broad incumbents

• Boston Scientific: Boston Scientific acquired Preventice Solutions (BodyGuardian) for ambulatory cardiac monitoring. A large incumbent with cardiac diagnostics, remote monitoring, and electrophysiology portfolio targeting similar hospital and cardiology customers.
• Philips: Philips offers patient monitoring and remote cardiac monitoring solutions used by hospitals and health systems. A broad incumbent with significant hospital telemetry and ICU monitoring market share.
• Hillrom (Baxter): Hillrom (now part of Baxter) acquired Bardy Diagnostics for ambulatory cardiac monitoring and competes in hospital cardiac monitoring through its Welch Allyn and patient monitoring portfolios. A broad incumbent with established hospital channels.
• GE HealthCare: GE HealthCare provides inpatient patient monitoring systems used in hospital ICUs and telemetry units where HEMOTAG competes for heart failure monitoring workflows. A broad incumbent with global hospital relationships.
• Medtronic: Medtronic offers the LINQ insertable cardiac monitor and broader cardiac diagnostics portfolio. A dominant incumbent with established hospital relationships, large salesforce, and deep reimbursement infrastructure across cardiac care.

Emerging players

• Bodyport: Bodyport is a startup developing a non-invasive cardiac monitoring scale that measures heart function through foot-pressure sensors for heart failure management. Most closely comparable emerging player targeting the same use case and customer segment.
• Biofourmis: Biofourmis provides AI-driven remote patient monitoring with a strong focus on heart failure management and hospital-at-home programs. Comparable emerging player in connected cardiac care for the same disease state.
• AliveCor: AliveCor's KardiaMobile is a consumer and clinical ECG device with AI-driven cardiac analysis. Comparable emerging player in non-invasive, mobile-connected cardiac monitoring sold through healthcare channels.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/hemotag

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Hemotag